927 related articles for article (PubMed ID: 16163245)
1. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
3. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
4. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M
J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214
[TBL] [Abstract][Full Text] [Related]
5. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
DiJoseph JF; Dougher MM; Kalyandrug LB; Armellino DC; Boghaert ER; Hamann PR; Moran JK; Damle NK
Clin Cancer Res; 2006 Jan; 12(1):242-9. PubMed ID: 16397048
[TBL] [Abstract][Full Text] [Related]
8. Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.
Nademanee A; Forman SJ
Semin Hematol; 2006 Oct; 43(4):240-50. PubMed ID: 17027658
[TBL] [Abstract][Full Text] [Related]
9. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Naparstek E
Curr Hematol Rep; 2005 Jul; 4(4):276-83. PubMed ID: 16009042
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
Martin P; Furman RR; Ruan J; Elstrom R; Barrientos J; Niesvizky R; Coleman M; Leonard JP
Semin Hematol; 2008 Apr; 45(2):126-32. PubMed ID: 18381108
[TBL] [Abstract][Full Text] [Related]
12. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
14. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
15. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.
DiJoseph JF; Goad ME; Dougher MM; Boghaert ER; Kunz A; Hamann PR; Damle NK
Clin Cancer Res; 2004 Dec; 10(24):8620-9. PubMed ID: 15623646
[TBL] [Abstract][Full Text] [Related]
16. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
18. Rituximab: review and clinical applications focusing on non-Hodgkin's lymphoma.
King KM; Younes A
Expert Rev Anticancer Ther; 2001 Aug; 1(2):177-86. PubMed ID: 12113023
[TBL] [Abstract][Full Text] [Related]
19. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518
[TBL] [Abstract][Full Text] [Related]
20. [Progress in therapeutic strategy for malignant lymphoma].
Ogura M
Gan To Kagaku Ryoho; 2005 Mar; 32(3):309-27. PubMed ID: 15791814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]